Friday, September 13, 2013
• Coronado Biosciences Inc., of Burlington, Mass., said it initiated a National Institutes of Health-sponsored Phase II study evaluating TSO (Trichuris suis ova, CNDO-201) for the treatment of ulcerative colitis (UC).
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.